IDH1 and central nervous system cancer: Amongst the molecular genetic alterations used to redefine glioma entities, the most common are mutations in the isocitrate dehydrogenase 1 and 2 (IDH1, IDH2) genes and the 1 p/19q co-deletion status [16,17,18].